Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
Clinical trial NCT03616301 · COMPLETED
Trial details
- NCT number
- NCT03616301
- Sponsor
- Pharmtechnology LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-28
- Primary completion
- 2018-08-13
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.